.2B, trading at NT1.60 on the TAI. This SniperIQ fundamentals page covers Apex Biotechnology's valuation (P/E 17.4x, P/B 1.7x), profitability (net margin 9.6%), revenue (NT1.60 on the TAI. Market cap moves with the live share price.

What is Apex Biotechnology's P/E ratio?

Apex Biotechnology's trailing twelve-month P/E ratio is 17.4x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Apex Biotechnology?

Apex Biotechnology runs a net profit margin of 9.6%, a gross margin of 28.6%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Apex Biotechnology generate?

Apex Biotechnology reported revenue of NT